- Home
- CELU vs DRRX Comparison
CELU vs DRRX Comparison
Compare CELU & DRRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELU
- DRRX
- Stock Information
- Founded
- CELU 2016
- DRRX 1998
- Country
- CELU United States
- DRRX United States
- Employees
- CELU N/A
- DRRX N/A
- Industry
- CELU Biotechnology: Pharmaceutical Preparations
- DRRX Biotechnology: Pharmaceutical Preparations
- Sector
- CELU Health Care
- DRRX Health Care
- Exchange
- CELU Nasdaq
- DRRX Nasdaq
- Market Cap
- CELU 40.9M
- DRRX 44.4M
- IPO Year
- CELU N/A
- DRRX 2000
- Fundamental
- Price
- CELU $2.46
- DRRX $1.01
- Analyst Decision
- CELU
- DRRX Buy
- Analyst Count
- CELU 0
- DRRX 2
- Target Price
- CELU N/A
- DRRX $5.00
- AVG Volume (30 Days)
- CELU 3.1M
- DRRX 68.2K
- Earning Date
- CELU 11-07-2024
- DRRX 11-13-2024
- Dividend Yield
- CELU N/A
- DRRX N/A
- EPS Growth
- CELU N/A
- DRRX N/A
- EPS
- CELU N/A
- DRRX N/A
- Revenue
- CELU $42,690,000.00
- DRRX $8,594,000.00
- Revenue This Year
- CELU N/A
- DRRX N/A
- Revenue Next Year
- CELU $233.89
- DRRX $3.07
- P/E Ratio
- CELU N/A
- DRRX N/A
- Revenue Growth
- CELU 182.02
- DRRX N/A
- 52 Week Low
- CELU $1.30
- DRRX $0.48
- 52 Week High
- CELU $7.97
- DRRX $1.88
- Technical
- Relative Strength Index (RSI)
- CELU 49.49
- DRRX 26.89
- Support Level
- CELU $3.26
- DRRX $1.27
- Resistance Level
- CELU $4.34
- DRRX $1.36
- Average True Range (ATR)
- CELU 0.84
- DRRX 0.11
- MACD
- CELU 0.11
- DRRX -0.04
- Stochastic Oscillator
- CELU 29.59
- DRRX 2.62
About CELU Celularity Inc.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from bio-banking segment.
About DRRX DURECT Corporation
Durect Corp is a biopharmaceutical company. It is engaged in the research, development, and manufacturing of pharmaceutical products. The company develops pharmaceutical products based on two categories which include new chemical entities and proprietary pharmaceutical programs. The company's pipeline products consist of DUR-928, POSIMIR, and others. Geographically, the company operates in the United States, Europe, Japan, and other countries, of which key revenue is derived from the Europe .